Avoralstat Disappoints in Patients With Hereditary Angioedema

A just-published trial suggests the oral plasma-kallikrein inhibitor avoralstat may cut the frequency of attacks in patients with severe hereditary angioedema (HAE). But as-yet-unpublished data from a subsequent, larger study dash those hopes, at least for the liquid formulation.